Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Development and validation of a cycle-specific risk score for febrile neutropenia during chemotherapy cycles 2-6 in patients with solid cancers: the CSR FENCE score

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Use of nonaspirin nonsteroidal anti-inflammatory drugs and risk of head and neck cancer: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cervical cancer risk in women living with HIV across four continents: A multicohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Change in mammographic density across birth cohorts of Dutch breast cancer screening participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cutaneous leishmaniasis with secondary mucosal disease in a traveller due to Leishmania (Viannia) braziliensis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The absolute risk reduction by prophylaxis in chemotherapy-induced febrile neutropenia (FN) is largest in patients at highest underlying risk. Therefore, reliable predictive models are needed. Here, we develop and validate such a model for risk of FN during chemotherapy cycles 2-6. A prediction score for risk of FN during the first cycle has recently been published1 . Patients with solid cancers initiating first-line chemotherapy in 2010-2016 were included. Cycle-specific risk factors were assessed by Poisson regression using generalised estimating equations and random split-sampling. The derivation cohort included 4,590 patients treated with 15,419 cycles, wherein 326 (2.1%) FN events occurred. Predictors of FN in multivariable analyses were: higher predicted risk of FN in the first cycle, platinum- or taxane-containing therapies, concurrent radiotherapy, treatment in cycle 2 compared to later cycles, previous FN or neutropenia, and not receiving granulocyte colony-stimulating factors. Each predictor added between -2 to 8 points to each patient's score (median score 4; interquartile range, 1-6). The incidence rate ratios for developing FN in the intermediate (score 1-4), high (score 5-6), and very high risk groups (score ≥7) were 7.8 (95% CI, 2.4-24.9), 18.6 (95% CI, 5.9-58.8), and 51.7 (95% CI, 16.5-162.3) compared to the low risk group (score ≤0), respectively. The score had good discriminatory ability with a Harrell's C-statistic of 0.78 (95% CI, 0.76-0.80) in the derivation and 0.75 (95% CI, 0.72-0.78) in the validation cohort (patient n=2,295, cycle n=7,670). The CSR FENCE score is the first published method to estimate cycle-specific risk of FN. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cancer
Vol/bind146
Udgave nummer2
Sider (fra-til)321-328
ISSN0020-7136
DOI
StatusUdgivet - 15 jan. 2020

ID: 56852222